乾癬治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Psoriasis - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0943
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年3月31日
◆ページ数:935
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥262,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD5,000 ⇒換算¥525,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD7,500 ⇒換算¥787,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Psoriasis – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Psoriasis – Pipeline Review, H1 2020, provides an overview of the Psoriasis (Immunology) pipeline landscape.

Psoriasis is a chronic skin condition caused by an overactive immune system. Symptoms of the disease include shedding of cells, flared up skin, itchiness, and burning sensation, swollen and stiff joints. Predisposing factors include heredity, side effects of certain medicines, stress, infections and environmental conditions. The condition may be controlled by topical or systemic medications and phototherapy.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Psoriasis – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Psoriasis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Psoriasis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 11, 27, 39, 60, 3, 138, 39 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 4 molecules, respectively.

Psoriasis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriasis (Immunology).
- The pipeline guide reviews pipeline therapeutics for Psoriasis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Psoriasis (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Psoriasis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Psoriasis (Immunology)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Psoriasis (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Psoriasis (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Psoriasis – Overview
Psoriasis – Therapeutics Development
Psoriasis – Therapeutics Assessment
Psoriasis – Companies Involved in Therapeutics Development
Psoriasis – Drug Profiles
Psoriasis – Dormant Projects
Psoriasis – Discontinued Products
Psoriasis – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Psoriasis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Psoriasis - Pipeline by 3SBio Inc, H1 2020
Psoriasis - Pipeline by AbbVie Inc, H1 2020
Psoriasis - Pipeline by Abcentra LLC, H1 2020
Psoriasis - Pipeline by AbClon Inc, H1 2020
Psoriasis - Pipeline by Abeome Corp, H1 2020
Psoriasis - Pipeline by AbGenomics International Inc, H1 2020
Psoriasis - Pipeline by Abivax SA, H1 2020
Psoriasis - Pipeline by Accuitis Pharmaceuticals Inc, H1 2020
Psoriasis - Pipeline by Aclaris Therapeutics Inc, H1 2020
Psoriasis - Pipeline by Actinobac Biomed Inc, H1 2020
Psoriasis - Pipeline by ActoBio Therapeutics Inc, H1 2020
Psoriasis - Pipeline by ADiTx Therapeutics Inc, H1 2020
Psoriasis - Pipeline by Aerie Pharmaceuticals Inc, H1 2020
Psoriasis - Pipeline by Affibody AB, H1 2020
Psoriasis - Pipeline by Affilogic SAS, H1 2020
Psoriasis - Pipeline by Agragen LLC, H1 2020
Psoriasis - Pipeline by Akeso Biopharma Inc, H1 2020
Psoriasis - Pipeline by Allianz Pharmascience Ltd, H1 2020
Psoriasis - Pipeline by Genentech Inc, H1 2020
Psoriasis - Pipeline by GeneScience Pharmaceuticals Co Ltd, H1 2020
Psoriasis - Pipeline by Genfit SA, H1 2020
Psoriasis - Dormant Projects, H1 2020
Psoriasis - Discontinued Products, H1 2020
Psoriasis - Discontinued Products, H1 2020 (Contd..1), H1 2020
Psoriasis - Discontinued Products, H1 2020 (Contd..2), H1 2020
Psoriasis - Discontinued Products, H1 2020 (Contd..3), H1 2020

【掲載企業】

3SBio Inc
AbbVie Inc
Abcentra LLC
AbClon Inc
Abeome Corp
AbGenomics International Inc
Abivax SA
Accuitis Pharmaceuticals Inc
Aclaris Therapeutics Inc
Actinobac Biomed Inc
ActoBio Therapeutics Inc
ADiTx Therapeutics Inc
Aerie Pharmaceuticals Inc
Affibody AB
Affilogic SAS
Agragen LLC
Akeso Biopharma Inc
Allianz Pharmascience Ltd
Almirall SA
Aluda Pharmaceuticals Inc
Alvotech ehf
AmDerma Pharmaceuticals LLC
Amgen Inc
Amicogen Inc
AnaptysBio Inc
AntalGenics SL
AnTolRx Inc
Apidel SA
Apimeds Inc
Applied Biology Inc
Arbor Pharmaceuticals LLC
Arcutis Biotherapeutics Inc
Arrien Pharmaceuticals LLC
AstraZeneca Plc
Athenex Inc
Atlantic Bio Sci LLC
Aurigene Discovery Technologies Ltd
Bayer AG
Beijing Fogangren Bio-Pharm Tech Co Ltd
Beijing Guiqianjin Medical Technology Co Ltd
Beijing Northland Biotech Co Ltd
Better Life Pharmaceuticals Inc
Bio-Thera Solutions Ltd
BioApex sro
Biocon Ltd
BioLingus AG
Biomendics LLC
Biomimetix JV LLC
BioXpress Therapeutics SA
BirchBioMed Inc
Boehringer Ingelheim International GmbH
Boston Pharmaceuticals Inc
Botanix Pharmaceuticals Ltd
Brickell Biotech Inc
Bristol-Myers Squibb Co
c-a-i-r Biosciences GmbH
C4X Discovery Holdings Plc
Can-Fite BioPharma Ltd
Canvax Biotech SL
Celon Pharma SA
CheckPoint Immunology Inc
ChemoCentryx Inc
Coegin Pharma AS
Coherus BioSciences Inc
Compugen Ltd
Crescita Therapeutics Inc
Curapel Ltd
Cythera Inc
Cytodyn Inc
Daiichi Sankyo Co Ltd
Dalriada Therapeutics Inc
DelArrivo Inc
Denali Therapeutics Inc
Dermavant Sciences Inc
DM Bio Ltd
DNX Biopharmaceuticals Inc
Dr. August Wolff GmbH & Co KG Arzneimittel
Eli Lilly and Co
ELORAC Inc
Emeriti Pharma AB
Enzychem Lifesciences Corp
Eolo Pharma
Escalier Biosciences BV
Eternity Bioscience Inc
Evelo Biosciences Inc
Exicure Inc
Fujifilm Kyowa Kirin Biologics Co Ltd
FunPep Co Ltd
FYB202 GmbH & Co KG
Galapagos NV
Galderma SA
Galectin Therapeutics Inc
Genentech Inc
GeneScience Pharmaceuticals Co Ltd
Genfit SA
Genrix (Shanghai) Biopharmaceutical Co Ltd
GlaxoSmithKline Plc
GlycoMar Ltd
Helix BioMedix Inc
Hengenix Biotech Inc
HitGen LTD
Huabo Biopharm Co Ltd
Hualan Biological Engineering Inc
Hydra Biosciences Inc
ILC Therapeutics Ltd
IMGENEX India Pvt Ltd
Immune Pharmaceuticals Inc
Immungenetics AG
Immunic Inc
Immunwork Inc
Impetis Biosciences Ltd
Innovent Biologics Inc
Innovimmune Biotherapeutics Inc
InSight Biopharmaceuticals Ltd
Inspyr Therapeutics Inc
Instituto Biomar SA
Istesso Ltd
Japan Tobacco Inc
JHL Biotech Inc
Jiangsu Hengrui Medicine Co Ltd
JiangSu Qyuns Therapeutics Co Ltd
Johnson & Johnson
JS InnoPharm (Shanghai) Ltd
Jubilant Biosys Ltd
Kadmon Corp LLC
Kaken Pharmaceutical Co Ltd
Kang Stem Biotech Co Ltd
Kangpu Biopharmaceuticals Ltd
Kine Sciences
Krystal Biotech Inc
Kv1.3 Therapeutics
Kymab Ltd
Lead Pharma Holding BV
Leo Pharma AS
Link Health Group
Lipidor AB
Lupin Ltd
Lycera Corp
Machavert Pharmaceuticals LLC
Maruho Co Ltd
Matrisys Bioscience Inc
MC2 Therapeutics AS
Merck KGaA
Metrion Biosciences Ltd
MetrioPharm AG
Mical Pharmaceuticals LLC
Midatech Pharma Plc
Mycenax Biotech Inc
Nektar Therapeutics
Nepsone ehf
Nestle Skin Health SA (Inactive)
NeuClone Pty Ltd
Nichi-Iko Pharmaceutical Co Ltd
Nimbus Therapeutics LLC
NKMAX Co Ltd
NovaLead Pharma Pvt Ltd
Novartis AG
Numab Innovation AG
One World Cannabis Ltd
Orphagen Pharmaceuticals Inc
OSE Immunotherapeutics
P & S Nano Ltd
Palo BioFarma SL
Panaxia Pharmaceutical Industries Ltd
Par'Immune SAS
Pfizer Inc
Pharmapraxis
Philogen SpA
PinCell srl
Polpharma Biologics
PRCL Research Inc
Principia Biopharma Inc
Progenra Inc
Promethera Biosciences SA
Protein Foundry LLC
Provectus Biopharmaceuticals Inc
Pyramid Biosciences Inc
Reata Pharmaceuticals Inc
RedHill Biopharma Ltd
Regranion LLC
Reliance Life Sciences Pvt Ltd
Revive Therapeutics Ltd
Rheos Medicines Inc
Rigel Pharmaceuticals Inc
RNAx Ltd
Samumed LLC
Sareum Holdings Plc
SBI Biotech Co Ltd
Servatus Ltd
SFA Therapeutics LLC
Shandong Boan Biological Technology Co Ltd
Shandong Danhong Pharmaceutical Co Ltd
Shanghai Celgen Bio-Pharmaceutical Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shulov Innovative Science Ltd
Siam Bioscience Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Sienna Biopharmaceuticals Inc
Singh Biotechnology LLC
Sinocelltech Ltd
siRNAgen Therapeutics Corp
Sol-Gel Technologies Ltd
Soligenix Inc
Spherium Biomed SL
sterna biologicals Gmbh & Co KG
Sun Pharma Advanced Research Company Ltd
Sunny BioDiscovery Inc
Suzhou Connect Biopharmaceuticals Ltd
Syntrix Biosystems Inc
Taro Pharmaceuticals USA Inc
Temisis Therapeutics
Tianjin Ever Union Biotechnology Co Ltd
Tianjin Hemay Pharmaceutical Co Ltd
Tonghua Dongbao Pharmaceutical Co Ltd
UCB SA
V Clinbio LLC
Vidasym Inc
Visionary Pharmaceuticals Inc
Voronoi
vTv Therapeutics Inc
Welichem Biotech Inc
Wellstat Therapeutics Corp
WntResearch AB
Wuhan Institute of Biological Products Co Ltd
Xbrane Biopharma AB
Yuhan Corp
Zai Lab Ltd
Zhejiang Hisun Pharmaceutical Co Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[乾癬治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆